Role of p38 MAPK in LPS induced pro-inflammatory cytokine and chemokine gene expression in equine leukocytes

Veterinary Immunology and Immunopathology

Volumn 129, Issue 3-4, 2009, Pages 192-199

  Neuder, Laura E ^a   Keener, Jamie M ^a   Eckert, Rachael E ^a   Trujillo, Jennifer C ^a   Jones, Samuel L ^a  

^a NORTH CAROLINA STATE UNIVERSITY   (United States)

Author keywords

Endotoxemia; Equine; Inflammation; Leukocytes; LPS; p38 MAPK

Indexed keywords

4 (4 FLUOROPHENYL) 2 (4 HYDROXYPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; 4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 8; LIPOPOLYSACCHARIDE; MITOGEN ACTIVATED PROTEIN KINASE P38; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; GENE EXPRESSION; HORSE; LEUKOCYTE; NONHUMAN; NUCLEOTIDE SEQUENCE; PROTEIN FUNCTION; REAL TIME POLYMERASE CHAIN REACTION; UPREGULATION;

ANIMALS; CELLS, CULTURED; CHEMOKINES; CYTOKINES; GENE EXPRESSION REGULATION; HORSES; LEUKOCYTES; LIPOPOLYSACCHARIDES; P38 MITOGEN-ACTIVATED PROTEIN KINASES; RNA, MESSENGER; SIGNAL TRANSDUCTION;

ANIMALIA; BACTERIA (MICROORGANISMS); EQUIDAE;

EID: 64749095050     PISSN: 01652427     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vetimm.2008.11.006     Document Type: Article

References (53)

1. Adrie C., and Pinsky M.R. The inflammatory balance in human sepsis. Intensive Care Med. 26 (2000) 364-375
2. Alluwaimi A.M. The cytokines of bovine mammary gland: prospects for diagnosis and therapy. Res. Vet. Sci. 77 (2004) 211-222
3. Badger A.M., Bradbeer J.N., Votta B., Lee J.C., Adams J.L., and Griswold D.E. Pharmacological profile of SB203580, a selective inhibitor of cytokine suppressive binding protein/p38 kinase, in animal models of arthritis, bone resorption, endotoxin shock and immune function. J. Pharmacol. Exp. Ther. 279 (1996) 1453-1461
4. Belknap J.K., Giguere S., Pettigrew A., Cochran A.M., Van Eps A.W., and Pollitt C.C. Lamellar pro-inflammatory cytokine expression patterns in laminitis at the developmental stage and at the onset of lameness: innate vs. adaptive immune response. Equine Vet. J. 39 (2007) 42-47
5. Bogaert L., Van Poucke M., De Baere C., Peelman L., Gasthuys F., and Martens A. Selection of a set of reliable reference genes for quantitative real-time PCR in normal equine skin and in equine sarcoids. BMC Biotechnol. 6 (2006) 24
6. Brady C.A., and Otto C.M. Systemic inflammatory response syndrome, sepsis, and multiple organ dysfunction. Vet. Clin. North Am. Small Anim. Pract. 31 (2001) 1147-1162 (v-vi)
7. Branger J., van den Blink B., Weijer S., Madwed J., Bos C.L., Gupta A., Yong C.L., Polmar S.H., Olszyna D.P., Hack C.E., van Deventer S.J., Peppelenbosch M.P., and van der Poll T. Anti-inflammatory effects of a p38 mitogen-activated protein kinase inhibitor during human endotoxemia. J. Immunol. 168 (2002) 4070-4077
8. Brooks A.C., Menzies-Gow N.J., Wheeler-Jones C., Bailey S.R., Cunningham F.M., and Elliott J. Endotoxin-induced activation of equine platelets: evidence for direct activation of p38 MAPK pathways and vasoactive mediator production. Inflamm. Res. 56 (2007) 154-161
9. Clerk A., and Sugden P.H. The p38-MAPK inhibitor, SB203580, inhibits cardiac stress-activated protein kinases/c-Jun N-terminal kinases (SAPKs/JNKs). FEBS Lett. 426 (1998) 93-96
10. Dauphinee S.M., and Karsan A. Lipopolysaccharide signaling in endothelial cells. Lab. Invest. 86 (2006) 9-22
11. Davies S.P., Reddy H., Caivano M., and Cohen P. Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem. J. 351 (2000) 95-105
12. Dean J.L., Brook M., Clark A.R., and Saklatvala J. p38 mitogen-activated protein kinase regulates cyclooxygenase-2 mRNA stability and transcription in lipopolysaccharide-treated human monocytes. J. Biol. Chem. 274 (1999) 264-269
13. Dean J.L., Sarsfield S.J., Tsounakou E., and Saklatvala J. p38 Mitogen-activated protein kinase stabilizes mRNAs that contain cyclooxygenase-2 and tumor necrosis factor AU-rich elements by inhibiting deadenylation. J. Biol. Chem. 278 (2003) 39470-39476
14. Detmers P.A., Zhou D., Polizzi E., Thieringer R., Hanlon W.A., Vaidya S., and Bansal V. Role of stress-activated mitogen-activated protein kinase (p38) in beta 2-integrin-dependent neutrophil adhesion and the adhesion-dependent oxidative burst. J. Immunol. 161 (1998) 1921-1929
15. Eckert R.E., Neuder L.E., Bell J.L., Trujillo J.C., and Jones S.L. The role of p38 mitogen-activated kinase (MAPK) in the mechanism regulating cyclooxygenase gene expression in equine leukocytes. Vet. Immunol. Immunopathol. 118 (2007) 294-303
16. Fijen J.W., Zijlstra J.G., De Boer P., Spanjersberg R., Tervaert J.W., Van Der Werf T.S., Ligtenberg J.J., and Tulleken J.E. Suppression of the clinical and cytokine response to endotoxin by RWJ-67657, a p38 mitogen-activated protein-kinase inhibitor, in healthy human volunteers. Clin. Exp. Immunol. 124 (2001) 16-20
17. Fitzgerald K.A., Rowe D.C., and Golenbock D.T. Endotoxin recognition and signal transduction by the TLR4/MD2-complex. Microbes Infect. 6 (2004) 1361-1367
18. Fontaine G.L., Belknap J.K., Allen D., Moore J.N., and Kroll D.L. Expression of interleukin-1beta in the digital laminae of horses in the prodromal stage of experimentally induced laminitis. Am. J. Vet. Res. 62 (2001) 714-720
19. Frantz B., Klatt T., Pang M., Parsons J., Rolando A., Williams H., Tocci M.J., O'Keefe S.J., and O'Neill E.A. The activation state of p38 mitogen-activated protein kinase determines the efficiency of ATP competition for pyridinylimidazole inhibitor binding. Biochemistry 37 (1998) 13846-13853
20. Garton N.J., Gilleron M., Brando T., Dan H.H., Giguere S., Puzo G., Prescott J.F., and Sutcliffe I.C. A novel lipoarabinomannan from the equine pathogen Rhodococcus equi. Structure and effect on macrophage cytokine production. J. Biol. Chem. 277 (2002) 31722-31733
21. Hale K.K., Trollinger D., Rihanek M., and Manthey C.L. Differential expression and activation of p38 mitogen-activated protein kinase alpha, beta, gamma, and delta in inflammatory cell lineages. J. Immunol. 162 (1999) 4246-4252
22. Herlaar E., and Brown Z. p38 MAPK signalling cascades in inflammatory disease. Mol. Med. Today 5 (1999) 439-447
23. Janicke H., Taylor P.M., and Bryant C.E. Lipopolysaccharide and interferon gamma activate nuclear factor kappa B and induce cyclo-oxygenase-2 in equine vascular smooth muscle cells. Res. Vet. Sci. 75 (2003) 133-140
24. Kotlyarov A., Neininger A., Schubert C., Eckert R., Birchmeier C., Volk H.D., and Gaestel M. MAPKAP kinase 2 is essential for LPS-induced TNF-alpha biosynthesis. Nat. Cell Biol. 1 (1999) 94-97
25. Laan T.T., Bull S., Pirie R.S., and Fink-Gremmels J. Evaluation of cytokine production by equine alveolar macrophages exposed to lipopolysaccharide, Aspergillus fumigatus, and a suspension of hay dust. Am. J. Vet. Res. 66 (2005) 1584-1589
26. Lali F.V., Hunt A.E., Turner S.J., and Foxwell B.M. The pyridinyl imidazole inhibitor SB203580 blocks phosphoinositide-dependent protein kinase activity, protein kinase B phosphorylation, and retinoblastoma hyperphosphorylation in interleukin-2-stimulated T cells independently of p38 mitogen-activated protein kinase. J. Biol. Chem. 275 (2000) 7395-7402
27. Lappas M., Permezel M., and Rice G.E. Mitogen-activated protein kinase proteins regulate LPS-stimulated release of pro-inflammatory cytokines and prostaglandins from human gestational tissues. Placenta 28 (2007) 936-945
28. Lasa M., Mahtani K.R., Finch A., Brewer G., Saklatvala J., and Clark A.R. Regulation of cyclooxygenase 2 mRNA stability by the mitogen-activated protein kinase p38 signaling cascade. Mol. Cell Biol. 20 (2000) 4265-4274
29. Lee J.C., Laydon J.T., McDonnell P.C., Gallagher T.F., Kumar S., Green D., McNulty D., Blumenthal M.J., Heys J.R., Landvatter S.W., et al. A protein kinase involved in the regulation of inflammatory cytokine biosynthesis. Nature 372 (1994) 739-746
30. Lee J.C., and Young P.R. Role of CSB/p38/RK stress response kinase in LPS and cytokine signaling mechanisms. J. Leukoc. Biol. 59 (1996) 152-157
31. Lohmann K.L., Vandenplas M., Barton M.H., and Moore J.N. Lipopolysaccharide from Rhodobacter sphaeroides is an agonist in equine cells. J. Endotoxin Res. 9 (2003) 33-37
32. Miyazawa K., Mori A., Miyata H., Akahane M., Ajisawa Y., and Okudaira H. Regulation of interleukin-1beta-induced interleukin-6 gene expression in human fibroblast-like synoviocytes by p38 mitogen-activated protein kinase. J. Biol. Chem. 273 (1998) 24832-24838
33. Moore J.N., and Barton M.H. Treatment of endotoxemia. Vet. Clin. North Am. Equine Pract. 19 (2003) 681-695
34. Moore J.N., Garner H.E., Shapland J.E., and Schaub R.G. Equine endotoxemia: an insight into cause and treatment. J. Am. Vet. Med. Assoc. 179 (1981) 473-477
35. Nick J.A., Avdi N.J., Young S.K., Lehman L.A., McDonald P.P., Frasch S.C., Billstrom M.A., Henson P.M., Johnson G.L., and Worthen G.S. Selective activation and functional significance of p38 alpha mitogen-activated protein kinase in lipopolysaccharide-stimulated neutrophils. J. Clin. Invest. 103 (1999) 851-858
36. Ono K., and Han J. The p38 signal transduction pathway: activation and function. Cell Signal. 12 (2000) 1-13
37. Palsson-McDermott E.M., and O'Neill L.A. Signal transduction by the lipopolysaccharide receptor, Toll-like receptor-4. Immunology 113 (2004) 153-162
38. Peng T., Lu X., Lei M., Moe G.W., and Feng Q. Inhibition of p38 MAPK decreases myocardial TNF-alpha expression and improves myocardial function and survival in endotoxemia. Cardiovasc. Res. 59 (2003) 893-900
39. Read M.A., Whitley M.Z., Gupta S., Pierce J.W., Best J., Davis R.J., and Collins T. Tumor necrosis factor alpha-induced E-selectin expression is activated by the nuclear factor-kappaB and c-JUN N-terminal kinase/p38 mitogen-activated protein kinase pathways. J. Biol. Chem. 272 (1997) 2753-2761
40. Ridley S.H., Sarsfield S.J., Lee J.C., Bigg H.F., Cawston T.E., Taylor D.J., DeWitt D.L., and Saklatvala J. Actions of IL-1 are selectively controlled by p38 mitogen-activated protein kinase: regulation of prostaglandin H synthase-2, metalloproteinases, and IL-6 at different levels. J. Immunol. 158 (1997) 3165-3173
41. Rodgerson D.H., Belknap J.K., Moore J.N., and Fontaine G.L. Investigation of mRNA expression of tumor necrosis factor-alpha, interleukin-1beta, and cyclooxygenase-2 in cultured equine digital artery smooth muscle cells after exposure to endotoxin. Am. J. Vet. Res. 62 (2001) 1957-1963
42. Shifflett D.E., Jones S.L., Moeser A.J., and Blikslager A.T. Mitogen-activated protein kinases regulate COX-2 and mucosal recovery in ischemic-injured porcine ileum. Am. J. Physiol. Gastrointest. Liver Physiol. 286 (2004) G906-913
43. Trivedi S., and Arasu P. Evaluation of endogenous reference genes for real-time PCR quantification of gene expression in Ancylostoma caninum. Mol. Biochem. Parasitol. 143 (2005) 241-244
44. Underwood D.C., Osborn R.R., Kotzer C.J., Adams J.L., Lee J.C., Webb E.F., Carpenter D.C., Bochnowicz S., Thomas H.C., Hay D.W., and Griswold D.E. SB239063, a potent p38 MAP kinase inhibitor, reduces inflammatory cytokine production, airways eosinophil infiltration, and persistence. J. Pharmacol. Exp. Ther. 293 (2000) 281-288
45. van den Blink B., Juffermans N.P., ten Hove T., Schultz M.J., van Deventer S.J., van der Poll T., and Peppelenbosch M.P. p38 mitogen-activated protein kinase inhibition increases cytokine release by macrophages in vitro and during infection in vivo. J. Immunol. 166 (2001) 582-587
46. Waguespack R.W., Kemppainen R.J., Cochran A., Lin H.C., and Belknap J.K. Increased expression of MAIL, a cytokine-associated nuclear protein, in the prodromal stage of black walnut-induced laminitis. Equine Vet. J. 36 (2004) 285-291
47. Werners A.H., Bull S., and Fink-Gremmels J. Endotoxaemia: a review with implications for the horse. Equine Vet. J. 37 (2005) 371-383
48. Winzen R., Kracht M., Ritter B., Wilhelm A., Chen C.Y., Shyu A.B., Muller M., Gaestel M., Resch K., and Holtmann H. The p38 MAP kinase pathway signals for cytokine-induced mRNA stabilization via MAP kinase-activated protein kinase 2 and an AU-rich region-targeted mechanism. EMBO J. 18 (1999) 4969-4980
49. Xu N., Chen C.Y., and Shyu A.B. Modulation of the fate of cytoplasmic mRNA by AU-rich elements: key sequence features controlling mRNA deadenylation and decay. Mol. Cell Biol. 17 (1997) 4611-4621
50. Young P.R., McLaughlin M.M., Kumar S., Kassis S., Doyle M.L., McNulty D., Gallagher T.F., Fisher S., McDonnell P.C., Carr S.A., Huddleston M.J., Seibel G., Porter T.G., Livi G.P., Adams J.L., and Lee J.C. Pyridinyl imidazole inhibitors of p38 mitogen-activated protein kinase bind in the ATP site. J. Biol. Chem. 272 (1997) 12116-12121
51. Zhong J., and Kyriakis J.M. Dissection of a signaling pathway by which pathogen-associated molecular patterns (PAMPs) recruit the JNK and p38 MAPKs and trigger cytokine release. J. Biol. Chem. (2007)
52. Zhu W., Downey J.S., Gu J., Di Padova F., Gram H., and Han J. Regulation of TNF expression by multiple mitogen-activated protein kinase pathways. J. Immunol. 164 (2000) 6349-6358
53. Zhu Y., Berg M., Fossum C., and Magnusson U. Proinflammatory cytokine mRNA expression in mammary tissue of sows following intramammary inoculation with Escherichia coli. Vet. Immunol. Immunopathol. 116 (2007) 98-103